AC Immune (NASDAQ:ACIU) Receives “Buy” Rating from HC Wainwright

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $16.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 389.30% from the stock’s current price.

Separately, StockNews.com cut shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st.

AC Immune Stock Up 5.8 %

Shares of NASDAQ ACIU opened at $3.27 on Wednesday. AC Immune has a 12-month low of $2.25 and a 12-month high of $5.14. The stock’s fifty day simple moving average is $3.27 and its two-hundred day simple moving average is $3.45.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $91.60 million. As a group, equities research analysts anticipate that AC Immune will post -0.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ACIU. Lazard Asset Management LLC acquired a new stake in AC Immune in the first quarter worth about $30,000. BNP Paribas Financial Markets boosted its stake in AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after purchasing an additional 8,423 shares in the last quarter. Silverberg Bernstein Capital Management LLC purchased a new stake in AC Immune during the 2nd quarter worth approximately $40,000. Vanguard Capital Wealth Advisors acquired a new position in AC Immune during the 2nd quarter valued at approximately $56,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of AC Immune by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after buying an additional 7,400 shares during the last quarter. 51.36% of the stock is owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.